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ABSTRACT
Mesenchymal stromal (stem) cells (MSCs) continue to be a
strong area of focus for academic- and industry-based
researchers who share the goal of expanding their thera-
peutic use for diverse inflammatory and immune-mediated
diseases. Recently, there has been an accelerated rate of
scientific publication, clinical trial activity, and commerci-
alisation in the field. This has included the reporting of
exciting new developments in four areas that will be of
key importance to future successful use of MSC-based
therapies in large numbers of patients: (a) fundamental
biology of the primary cells in bone marrow and other tis-
sues that give rise to MSCs in culture. (b) Mechanisms by
which MSCs modulate immune and inflammatory
responses in vivo. (c) Insights into MSC kinetics, safety,
and efficacy in relevant animal disease models. (d)
Isolation, definition, and clinical trial-based testing of
human MSCs by biomedical companies and academic
medical centers. Despite this progress, it remains unclear
whether MSCs will enter mainstream therapeutic practice
as a frequently used alternative to pharmacotherapy or
surgical/radiological procedures in the foreseeable future.
In this review, we summarize some of the most significant
new developments for each of the four areas that contrib-
ute to the process of translating MSC research to the clini-
cal arena. In the context of this recent progress, we
discuss key challenges and specific knowledge gaps which,
if not addressed in a coordinated fashion, may hinder the
creation of robust “translational pipelines” for consolidat-
ing the status of MSC-based therapies. STEM CELLS
2013;31:2033–2041
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INTRODUCTION
The past two decades have seen an explosion of scientific and
clinical interest in mesenchymal stromal (stem) cells (MSCs)
driven by the over-riding premise that culture-expanded
MSCs will soon become a widely prescribed therapeutic agent
for diverse acute and chronic diseases. While therapeutic
interest in MSCs initially centered upon harnessing their
capacity for multilineage differentiation to directly regenerate
tissues and organs [1,2], they are now also viewed as potent
“trophic” modulators of disease-associated tissue microenvir-
onments [3]. Thus, the current translational landscape for
MSCs includes therapeutic models involving direct tissue
regeneration as well as indirect, modulatory effects on dam-
aged and diseased tissues [4]. This latter concept has placed
the anti-inflammatory and immunomodulatory properties of
MSCs front and center in much of the recently published lit-
erature (Fig. 1A) [5–7]. The capacity of MSCs to broadly
modify the activity of most major components of the innate
and adaptive immune system is now seen, along with their
proangiogenic, cytoprotective, and antifibrotic effects, as an
essential component of their therapeutic potential for many
disease targets [3,6]. The observations that MSCs migrate
toward sites of inflammation and are triggered (or “licensed”)
to become more potent by inflammatory cytokines and pattern
recognition receptor (PRR) ligands [6,7] have further strength-
ened the belief that a single localized or systemic administra-
tion of unmodified MSCs can be expected to actively
“reprogram” an inflammatory milieu towards repair and
regeneration.
However, while quite a large number of clinical trials
based on this concept have been completed or are under way
[6,8–13], it remains unclear whether MSCs will soon become
a successful, widely prescribed therapy for inflammatory dis-
eases [14]. In comparison with new pharmacological agents,
it appears worrisome that MSC therapies are being trialed
simultaneously for such a wide range of diseases in the con-
text of incomplete understanding of their mechanisms of
action and in an evolving regulatory environment [4,15,16].
In this Concise Review, we critically examine the progress
that is being made toward translating knowledge of MSC
biology and immunomodulatory effects to widespread clinical
use for diseases which share the common feature of damaging
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acute or chronic immunological activity. Initially, we high-
light some of the most exciting recent developments that have
occurred in four key areas of relevance to successful clinical
translation - fundamental stem cell biology, mechanistic cellu-
lar studies, preclinical diseases models, and cell manufacture/
clinical trials (Fig. 1B). We then discuss how these new
developments are influencing therapeutic protocols, the degree
to which a robust translational pipeline is emerging for a
range of inflammatory diseases and the future strategies that
could positively impact eventual benefits to patients and
communities.
RECENT PROGRESS IN UNDERSTANDING
PRIMARY MSCS AND THEIR IN VIVO
LOCATIONS AND FUNCTIONS
Until quite recently, the identity, diversity and physiological
functions of the cells in bone marrow and other tissues that
expand in plastic-adherent culture to generate MSCs were not
clearly known and there were important misconceptions about
their status as stem cells [4]. In the past 5 years, however,
significant progress has been made by groups with expertise
in fundamental stem cell biology in elucidating the in vivo
biology of the tissue-resident cells from which culture-
expanded MSCs are derived [4].
In the mouse, Morikawa et al. demonstrated that a subset
of MSCs could be prospectively identified and purified from
bone marrow using the surface proteins platelet-derived
growth factor receptor (PDGFR)a and stem cell antigen
(Sca)21 [17]. This identification subsequently allowed for the
localization of the primary MSC subset to the peri-vascular
region of arteries in cortical bone. In this study, the
PDGFRa1/Sca-11 cells were capable of repopulating a simi-
lar bone marrow niche when transplanted into new recipients
directly after purification [17]. Using an in vivo ablation
approach, Omatsu et al. showed that mouse bone marrow
cells that abundantly express CXCL12 and are primarily
located close to peri-sinusoidal endothelium (which they
termed CXCL12-abundant reticular cells (CAR) cells) play an
important role in maintaining hematopoietic stem cell (HSC)
proliferation in addition to serving as progenitors for osteo-
blasts and adipocytes [18]. Similarly, Mendez-Ferrer et al.
reported that peri-vascular bone marrow stromal cells express-
ing nestin are closely co-associated with HSCs and account
for all of the MSC content of mouse bone marrow cultures.
Furthermore, cultured nestin1 MSCs were capable of self-
renewal, contributed to physiological bone and cartilage turn-
over following transplantation and were required for HSC
maintenance in vivo [19]. Subsequently, Ding et al. demon-
strated that stem cell factor (SCF)-producing peri-vascular
stromal cells expressing multiple MSC-associated markers
were required for maintenance of the mouse bone marrow
HSC niche. In this study, however, the identified cells were
found to express the leptin receptor but not nestin [20].
Greenbaum et al. further revealed the complexity of bone
marrow stromal subsets by selectively deleting CXCL12
expression from osteoblasts, endothelial cells and individual
stromal subpopulations in the mouse. This study indicated the
presence of separate MSC subpopulations that express the
Figure 1. Progression of interest in the immunological properties of MSCs: (A): Left: A graphical representation of total mesenchymal stem cell (MSC)-
related publications between January 1993 and March 2013 and the subset of these that address immune response and inflammation. Right: A summary of the
PubMed search strategy used to generate data on MSC-related publications. (B): An illustration of the “Pipeline” of key research areas contributing to the pro-
cess of translating knowledge of MSC paracrine properties toward the treatment of human inflammatory diseases. Abbreviation: MSC, mesenchymal stem cell.
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transcription factors osterix and PRX1 and which support
different aspects of hematopoiesis [21]. In this study, the
PRX11, CXCL12-expressing MSC subset was negative for
both nestin and leptin receptor suggesting that it may repre-
sent a precursor to cell populations identified in the other
reports [21]. Mourcin et al. identified two subsets of mouse
marrow stromal cells which express galectin-1 and interleukin
(IL)27 respectively. These are differentially localized and
play distinct roles in B cell development [22]. Finally, Park
et al. specifically sought out marrow stromal cells responsible
for bone regeneration using promoter-specific lineage tracing
in mice. They demonstrated that an “MSC-like” cell popula-
tion expressing the transcription factor myxovirus resistance-1
(Mx1), serves as a progenitor for osteoblasts following bone
fracture and demonstrates characteristics of bona fide stem
cells in single-cell and serial transplantation experiments [23].
Although it is clear that some conflicting observations
remain to be resolved, these recent studies in mouse have pro-
vided essential insights into the physiological nature of
MSCs—in particular, their functional roles in maintaining the
HSC niche and in bone regeneration. Taken together, the
emerging evidence supports the conclusions that cells which
serve as precursors to culture-expanded MSCs represent bona
fide progenitor cells in vivo and can be prospectively identified
by their expression of several functionally important proteins. In
bone marrow, they now seem likely to consist of multiple indi-
vidual cell types residing in peri-vascular spaces within the cen-
tral sinusoidal region and at the endosteal surfaces.
Some equally important work has been carried out in
human cell and tissue samples. For example, Battula et al.
[24], Maijenberg et al. [25], and Tormin et al. [26] have
recently reported results of fluorescence activated cell sorting
(FACS)-based purification of stromal cell populations from
human bone marrow using multiple cell surface markers
including CD271, CD56, and MSCA-1 (now known to be tis-
sue non-specific alkaline phosphatase) and CD146 [24–26].
These studies appear to confirm the presence of multiple sub-
sets of human primary MSCs, which may differ in their dif-
ferentiation capacities as well as in their relative abundance
during fetal development and aging [24–26]. The study of
Tormin et al. also localized two distinct MSC subsets within
human bone marrow—CD2711/CD1461 cells in peri-vascular
regions and CD2711/CD146- cells at endosteal surfaces [26].
Furthermore, Crisan et al. demonstrated that cells which are con-
fined to peri-vascular regions and express the pericyte markers
CD146 and NG2 can be purified by FACS from multiple human
tissues including skeletal muscle, pancreas, fat, placenta and
bone marrow. These cells natively co-express typical MSC sur-
face proteins and give rise to multipotent MSCs in long-term
cultures [27]. Although conceptually in keeping with findings
that have emerged from the mouse literature, these studies also
highlight the lack of MSC- and MSC-subset-specific markers
that apply equally to experimental species and to humans.
From a translational perspective, these recent basic
insights highlight the fact that a better appreciation of the het-
erogeneity of MSC subpopulations within the bone marrow
and of MSC-like pericytes derived from other tissues will
serve to improve systems for defining therapeutic MSCs at
the point of isolation and for optimizing their potency for spe-
cific disease targets. Similarly, the growing understanding of
the embryological origins of perivascular cells within individ-
ual organ and tissue systems, the signaling pathways involved
in their recruitment and function and the roles they play in
vascular development and postnatal vascular repair (reviewed
in detail by Armulik et al. [28]) has potential to critically
inform future clinical strategies for MSC-based tissue regener-
ation and immunomodulation.
RECENT PROGRESS IN UNDERSTANDING THE
MECHANISMS OF INTERACTION BETWEEN
MSCS AND IMMUNE/INFLAMMATORY CELLS
Substantial progress has been made recently in our under-
standing of the interactions between MSCs and immune cells.
As a result of such studies, MSCs are now considered to
intuitively respond to their immediate environment and to
adapt their response accordingly through the release of solu-
ble factors such as prostaglandin E2 (PGE2), kyneurenine,
interleukin (IL)-10, tumor necrosis factor (TNF)-stimulated
gene 6 protein (TSG-6), nitric oxide (NO), and transforming
growth factor (TGF-b)-1 [29–34] and/or through cell contact
signaling such as Notch, and CD95/Fas [35–37]. This multi-
faceted responsiveness is in keeping with an emerging under-
standing of the role of primary MSCs in regulating, along
with macrophages and other cell types, the bone marrow stem
hematopoietic cell niche [38].
A number of recent studies have elegantly demonstrated
the response of culture-expanded MSCs to different environ-
mental cues. Utilizing a mouse sepsis model, Nemeth et al.
conclusively revealed an in vivo anti-inflammatory effect
mediated by MSCs through promotion of IL-10-producing
alternatively activated macrophages in the lung. In this model,
lipopolysaccharide- and TNF-a activated NF-jB signaling
through toll like receptor-4 and TNF receptor 1, led to expres-
sion of cyclooxygenase (COX)22, and subsequent PGE-2
production by MSCs. This facilitated MSC interaction with
macrophages through EP2 and EP4 receptors and resulted in
increased macrophage production of IL-10 [34]. The group of
Prockop et al. have documented an alternative anti-
inflammatory mechanism of human MSCs transferred into
rodent recipients in the context of inflammatory injury models
such as acute myocardial infarction, ischemic stroke and peri-
tonitis [7]. This mechanism involves secretion by MSCs of
TSG-6, an anti-inflammatory glycoprotein, in response to
TNF-a produced by macrophages [7].
Context-dependent modification of T-helper (Th)1/Th2
balance by MSCs has also been demonstrated in a number of
disease models, including a Th2-driven model of ragweed-
induced allergic asthma. In this report, MSC administration
was associated with reduced serum and bronchioalveolar
lavage fluid levels of IL-4 and IL-13, reduced levels of IgG1
and IgE and impeded inflammatory cell infiltration and mucus
deposition in the lungs. The activation of IL-4R/STAT-6 sig-
naling in MSCs resulted in an increase in TGF-b1 production,
which was proposed to be responsible for an increase in regu-
latory T-cell (Treg) numbers [33]. A significant number of
additional studies have also demonstrated the capacity for
MSCs to promote/expand Treg in vitro and in vivo. This
effect has been linked with induction of TGF-b1
[30,32,35,39]. as well as idoleamine 2,3 dioxygenase [31]. In
a number of recent reports, the importance of Treg in media-
ting beneficial effects of MSCs in vivo has been unequivo-
cally demonstrated using Treg depletion [31,32].
Proinflammatory T-helper 17 (Th17) cell differentiation is
also modulated by MSCs, in some cases in favor of the gener-
ation of Treg [6,39,40]. In the case of Th17 suppression,
MSCs have been shown to mediate their effect through a
contact-dependent mechanism involving induction in MSCs of
COX-2/PGE2 and modulation of responder T-cells via the
PGE2 receptor EP4 [40]. In human T-cells, MSC-mediated
inhibition of Th17 differentiation was associated with upregu-
lation of the transcription factor FOXP3 and induction of an
IL-10-producing Treg phenotype [39]. Further evidence of a
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role for cell contact-dependent signaling was recently reported
by Akiyama et al. who showed that MSC administration in a
mouse model of experimental colitis led to reduction in Th17
cells and increase in Treg. In this model, CD95L (FAS
Ligand) signaling by MSCs resulted in increased apoptosis of
activated effector T-cells and macrophage-derived TGF-b1,
produced in response to T-cell apoptosis, leading to an
increase in Treg [35]. Using human cells in vitro, Quaedack-
ers et al., demonstrated that activated CD81 and CD41 T-
cells were specifically modulated through binding to adipose-
derived MSCs [41]. Finally, Ren et al. have demonstrated that
MSCs suppress T-cell responses through the coordinated pro-
duction of chemoattractants and NO in the context of an
inflammatory environment. Interestingly, however, in the
absence of NO, the influence of MSCs was reversed and
resulted in increased T-cell proliferation [42].
Along with macrophages and T-cells, dendritic cells
(DC) play a key role in disease-associated immune and
inflammatory responses and are also subject to MSC modu-
lation. In various studies, MSCs have been demonstrated to
modulate DC maturation, migration, and antigen presentation
and to induce a tolerogenic DC phenotype [36,37,43]. Initial
in vitro observations regarding MSC attenuation of DC
migration [43] have now been substantiated in an in vivo
model [44]. Regarding the mediators of MSC-associated DC
modulation, IL-6 has been shown to play a partial role in
the inhibition of DC maturation [43,45], while more recent
studies have also identified a role for the Notch signaling
pathway [36,37].
MSCs may also mediate context-dependent effects on
the activity of other innate and adaptive immune cells that
are involved in inflammatory disease pathogenesis [6]. For
example, in vitro studies of MSC interactions with natural
killer (NK)-cells indicate cross-talk between the two cell
types that is mediated both by cell–cell contact and by solu-
ble mediators [6,46]. Depending on the cytokine milieu and
the activation state of the NK-cell, this cross-talk may result
in inhibition of NK-cell proliferation and cytolytic capacity
or in NK-cell-mediated lysis of MSCs [46]. Although rela-
tively under-investigated, direct and indirect modulatory
effects of MSCs on B-cells and antibody responses have also
been demonstrated [47]. Interestingly, results of in vitro
studies to date have provided somewhat contradictory results
with evidence for both suppression and promotion by MSCs
of key B-cell biological responses including survival, prolif-
eration, immunoglobulin production, and plasma cell differ-
entiation. Similarly, in vivo models of antibody-mediated
disease, most notably models of systemic lupus erythemato-
sis and organ transplantation, have yielded evidence of both
beneficial and detrimental effects of MSC administration
[47].
Taken together, recent mechanistic studies using both in
vitro and in vivo systems document complex interactions
between MSCs and their immediate environment, which result
in key modulatory effects on a range of immune effector cell
types. Importantly, earlier studies focused on identifying indi-
vidual factors responsible for immunosuppressive effects of
MSCs have progressed to mechanistic insights that reveal
coordinated “cross-talk” between MSCs and immune/inflam-
matory cells involving signals from multiple cell-surface and
secreted factors [34]. On-going elucidation of the relative
roles of contact-dependent signals and soluble mediators in
directing these effects remains very cogent to their successful
clinical translation. Specifically, new insights into mechanism
of action will continue to influence key aspects of clinical
trial design such as route and site of MSC administration,
optimization of MSC anti-inflammatory phenotype and,
eventually, the potential for replacing the cells themselves
with individual mediators, mediator “cocktails” or subcellular
vesicles.
RECENT PROGRESS IN THE USE OF
PRECLINICAL MODELS OF INFLAMMATORY
DISEASE TO GUIDE CLINICAL TRANSLATION
In addition to serving as a testing ground for therapeutic effi-
cacy and mechanism of action, preclinical animal models also
provide important indications of MSC safety, toxicity, phar-
macodynamics, and pharmacokinetic profiles that may be of
relevance to future widespread human clinical use. One
important consideration in this regard relates to the influence
of MSC administration on new or preexisting cancers [48–
50]. Recent reports of the context-dependent role of MSCs in
regulating tumor growth speak to the complexity of this issue
[48,51,52]. While Lee et al. reported that weekly infusions of
preactivated human MSCs enhanced tumor-suppressive activ-
ity in a mouse xenograft tumor model [51], Ren et al. demon-
strated that tumor-resident MSCs recruit monocyte/
macrophages via the chemokine CCR2 with resulting
enhancement of tumor growth [52]. The latter finding is in
keeping with the reprogramming effect of MSCs on macro-
phages in an inflammatory environment but emphasizes the
fact that such effects may be detrimental in settings such as
neoplasia.
Preclinical models have also provided important opportu-
nities for evaluating the immune responses induced by alloge-
neic MSCs (allo-MSCs) under varying conditions [5]. Allo-
MSCs are considered to be poorly immunogenic in compari-
son with commonly transplanted cells and tissues and the
concept of immune privilege, whereby allo-MSCs fail to elicit
any active anti-donor immune response in vivo, has been an
important tenet of the “off-the-shelf” model of human MSC
therapies [3,6]. However, a number of recent animal model
studies provide evidence that allo-MSCs do, in fact, promote
detectable antidonor immunity in nonimmunosuppressed hosts
[5]. For example, Schu et al. demonstrated that intravenous
(i.v.) injection of allo-MSCs in rat results in the formation of
alloantibodies, which may contribute to the rapid clearance of
a second cell inoculum [53]. Moreover, in a rat model of
post-myocardial infarction (MI) cardiac repair, Huang et al.
showed that in vivo differentiation of locally implanted allo-
MSCs is associated with the development of antidonor T-cell
and antibody responses which resulted in loss of long-term
benefits for cardiac function [54].
A related area for which animal models represent an
essential testing ground is the in vivo distribution, fate and
longevity of MSCs administered by various routes. Within the
past year, some notable studies have revisited the phenom-
enon of MSC entrapment in the liver and lungs of rodents fol-
lowing i.v. injection to better determine its importance for
clinical applications [53,55–58]. In most settings, almost all
i.v. injected MSCs have been shown to remain in the lungs
and liver, casting doubt on whether direct MSC/immune cell
contact is likely to occur at other sites [55,57]. This phenom-
enon of entrapment is not inconsistent with immunosuppres-
sive/anti-inflammatory effects of administered MSCs at
distant sites but would imply that the entrapped cells either
inherently produce soluble immunosuppressive mediators that
act systemically or, more likely, interact with monocyte/mac-
rophages in the lungs and/or liver to induce the production of
anti-inflammatory factors such as IL-10 [34]. However, as
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recently reported by Nystedt et al., the extent of lung adhe-
sion may vary depending on cell size, passage number, MSC
source and expression of adhesion molecules and matrix com-
ponents such as CD49 and fibronectin [56]. Furthermore, in
both rat and mouse, distribution and persistence of injected
MSCs to multiple lymphoid and nonlymphoid, including peri-
vascular engraftment, have been demonstrated [53,58]. The
degree to which these diverse observations from animal
experimentation are replicated in human MSC recipients is
poorly understood at present.
Taken together, the recent literature from a wide variety
of preclinical animal models provides a wealth of potentially
valuable information regarding mechanisms of action, safety,
immunogenicity, and in vivo kinetics of therapeutically
administered MSCs. Preclinical studies also continue to reveal
promising new disease targets with some notable recent
examples being acute lung injury [59,60] and corneal injury/
transplantation [61,62]. As we discuss in the concluding sec-
tion of this review, however, the diffuse and variable nature
of animal experimentation has also created a complex land-
scape for progress from preclinical to clinical studies. In addi-
tion, results pertaining to MSC influences on disease
pathophysiology or potential for adverse effects such as
entrapment and tumorigenesis in animal models should be
interpreted with a measure of caution as regards to their direct
applicability to human subjects.
RECENT PROGRESS IN THE DEVELOPMENT OF
COMMERCIALLY VIABLE CELL PRODUCTS AND
THE EXECUTION OF CLINICAL TRIALS
Human therapy with culture-expanded MSCs has moved well
beyond the proof-of-concept phase. Since the first reported
clinical trial of MSCs in 1995 [63], more than 100 clinical tri-
als involving over 3,000 human subjects have met safety end-
points [10] and a large number of phase two third efficacy
trials are close to conclusion. Strikingly, no severe adverse
events caused by MSC administration have been reported
from these trials to date, providing an impetus for large-scale
development of MSC-based products [10]. In May 2012, the
biotechnology company Osiris Therapeutics Inc. (Columbia,
MD, http://www.osiris.com/) received market approval in
Canada and New Zealand for a proprietary MSC formulation
(Prochymal) to treat specific pediatric cases of graft versus
host disease (GvHD)—representing the first market-approved
allogeneic (“off-the-shelf”) stem cell medicine. Prochymal is
now undergoing phase II/III trials for inflammatory bowel dis-
ease (IBD), MI, chronic obstructive pulmonary disease, and
type-1 diabetes mellitus. Several other major commercial
developers of MSC-based therapeutics with competing sour-
ces and methods of formulation are also trialling their prod-
ucts across a range of clinical indications. These include
Athersys Inc. (Celveland, OH, http://www.athersys.com/,
product Multistem, in phase II trials for IBD and ischemic
stroke); Stempeutics (Bangalore, India, http://www.stempeu
tics.com/, product Stempeucel, in phase II trials for osteoar-
thritis, ischemic stroke, liver cirrhosis, and critical limb ische-
mia); Mesoblast Inc. (Melbourne, Australia, http://
www.mesoblast.com/, products Revascor and NeoFuse, in
phase II trials for heart failure, MI, type 2 diabetes mellitus
and degenerative disc and joint disease); TiGenix NV
(Leuven, Belgium, http://www.tigenix.com/, product Cx601,
in phase II and III trials for rheumatoid arthritis and fistuliz-
ing IBD); Celgene Cellular Therapeutics (Warren, NJ, http://
www.celgene.com/, product PDA-001, in phase I and II trials
for MS, sarcoidosis, ischemic stroke, rheumatoid arthritis and
IBD) and Pluristem Therapeutics (Haifa, Israel, http://
www.pluristem.com/, product PLX-PAD cells, in phase II
trial for peripheral artery disease).
In parallel with these industry-driven initiatives, there
have been numerous recent clinical trials of culture-expanded
MSCs completed entirely within university- and academic
medical center-based systems. Although it is not possible to
comprehensively review all of these studies here, it is notable
that human trials of MSC therapy have been reported from
academic centers across Europe, North America, and Asia
and have involved both autologous and allogeneic MSC sour-
ces. Some important recent examples that have specifically
provided new evidence of MSC safety and/or efficacy include
a large trial of autologous MSC “induction” therapy in living
donor kidney transplant recipients from China [11], a phase I/
II trial comparing trans-endocardial injection of autologous
and allogeneic MSCs for ischemic cardiomyopathy from the
USA [13], a multicenter phase II study of MSC infusions for
steroid-resistant GvHD in recipients of allogeneic bone mar-
row transplant from Europe [9], and phase I/II studies of i.v.
and localized autologous MSCs for Crohn’s disease from Italy
and the Netherlands [8,12].
HOW CAN COHESIVE TRANSLATIONAL
PIPELINES BE DEVELOPED FOR MSC
THERAPEUTICS?
As we have reviewed in the preceding sections, research and
technology focused on MSCs has yielded a wealth of exciting
new insights, concepts and clinical observations which appear
to lend further support to their therapeutic value in inflamma-
tory diseases. Despite this progress, however, the future of
MSC administration as a widely applied therapeutic interven-
tion currently seems far from assured. To the unbiased eye,
the field appears vulnerable on several fronts including: (a)
the unequivocal documentation of safety and efficacy in Phase
III and long-term (Phase IV) post-marketing studies, (b) the
ability of cell manufacturers and clinical trialists to keep pace
with emerging regulatory frameworks for advanced therapy
medicinal products, and (c) the degree to which new scientific
insights can be practically incorporated into therapeutic prod-
ucts. Furthermore, and in contrast to translational pathways
that have proved successful for other therapies such as new
drug classes, disease-modifying biological agents and medical
devices, the anti-inflammatory and immunomodulatory prop-
erties of MSCs are being investigated and applied with vary-
ing degrees of cohesion to a very broad range of disease
processes with diverse pathophysiological features. Thus, it is
reasonable to ask whether strong translational “pipelines” will
emerge from current worldwide research trends. For each of
the four areas we have addressed in this article, there have
been developments that could clearly facilitate future success
in the clinical arena. However, there are also persistent
knowledge gaps which, if left unaddressed, may significantly
hamper progress (Fig. 2). Thus, we believe that there are
some important challenges to be considered by both the aca-
demic- and industry-based communities to ensure a more
cohesive overall effort toward widespread clinical application
of MSC-based therapies in the coming years.
For researchers focusing on cell mechanism and preclini-
cal MSC studies, the means by which experimental observa-
tions can be linked to clinical applications remains
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problematic. As interest in the field has grown, studies per-
formed in culture systems and in animal models have raised
many, sometimes contradictory, possibilities regarding MSC
diversity, mechanism of action, efficacy, and safety that merit
testing in human subjects. While the cumulative knowledge
gained is of undoubted value on several fronts, a large num-
ber of studies are performed in isolation from focused transla-
tional projects. One strategy that could be pursued to better
connect preclinical and clinical investigations in the MSC
field is the formation of multidisciplinary, interinstitutional
networks to collaboratively target specific disease categories
across a full spectrum of research and technical skills. In fact,
some good examples exist of collaborative groups driving the
rational translation of MSC-based therapy in the areas of
organ transplantation and hematological malignancies [9,64].
The combined expertise of such networks allows for optimal
selection and interpretation of animal models as well as pur-
poseful preclinical testing of administration regimens that can
be subsequently translated to human subjects. A network-
based approach is also likely to exert a more cohesive and
positive influence upon the development of regulatory stand-
ards and best practice guidelines as the field evolves [15]. A
related area for which network-based collaboration between
basic and clinical research groups would be of high value is
in the development of mechanistically informed strategies for
monitoring MSC potency, efficacy, and safety in human clini-
cal trial subjects. An important issue which remains poorly
addressed in the field at present is the gap that exists between
our understanding of MSC anti-inflammatory and immune
modulatory mechanisms in culture/animal model systems and
our ability to measure the contribution and potency of such
mechanisms in human subjects receiving MSC therapies.
Additionally, the clinical implications of anti-donor T-cell and
antibody responses induced in vivo by allogeneic MSCs
remain poorly understood [5]. Further coordinated effort from
laboratory-based immunologists and clinical researchers will
be of value in better addressing these areas.
For clinical researchers and commercial entities develop-
ing therapeutic MSC products, several key issues threaten to
impede progress. In the first place, the majority of clinical-
grade MSCs generated by commercial entities or academic
medical centers are isolated by plastic adherence and consti-
tute heterogeneous cell populations. As future regulatory
guidelines are likely to dictate that methods to prospectively
define and purify MSCs from their primary source tissues be
developed [15,16], such plastic adherent cells may fall short of
emerging standards. Prospective purification of primary MSCs
on the basis of specific cell surface markers such as alkaline
phosphatase (Stro3) and CD271 represents one promising
strategy for addressing this issue [4,24,25,65,66]. It is impor-
tant to emphasize, however, that these and other individual
markers are not unique to MSCs in their various in vivo niches
Figure 2. An illustration of key challenges and knowledge gaps
related to four major research themes associated with clinical transla-
tion of mesenchymal stem cells to widespread clinical use. Abbrevia-
tions: MSC, mesenchymal stem cell; NK, natural killer.
Table 1. Recent research and technology contributions to the rational clinical translation of immunomodulatory mesenchymal stem cell ther-
apy for graft versus host disease
Contribution Relevance to translation
Identification of primary stromal cell subtypes along
Identification of primary stromal cell subtypes along
with their developmental origins, locations, marker
expression, migration characteristics, and response
to environmental cues
Prospective isolation of optimal MSC population
Opportunities to modify biodistribution and enhance
therapeutic efficacy
[17–22,24–28]
Identification of biomarkers of MSC therapeutic
response in GvHD
Optimisation of patient selection
Development of tailored therapeutic administration
[72]
Identification of mechanisms of MSC elimination fol-
lowing in vivo administration
Establishment of optimal culture conditions and dos-
ing regimen
Improvement of patient safety
[68,73]
Detailed investigation of MSC biodistribution in rele-
vant preclinical models of GvHD and human
recipients
Improved understanding of pharmacokinetic and safety
profiles
[71,74]
Correlation of passage number and culture conditions
with therapeutic response in GvHD
Minimisation of cell dose
Optimisation of therapeutic efficacy
[69,70]
Achievement of regulatory standards for use of MSC
therapeutic products in GvHD
Facilitation of phase II, III and phase IV clinical trials [9,70,75]
Extended follow-up of patients receiving MSCs for
GvHD in the context of multicenter clinical trial
networks
Cumulative record of disease-specific safety and
efficacy
[9,69,75]
Abbreviations: GvHD, graft versus host disease; MSC, mesenchymal stem cell.
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and that their expression during culture expansion is subject to
change and susceptible to variability based on culture condi-
tions [4]. In addition, it is not clear whether the culture condi-
tions currently used to propagate MSCs provide optimal
support for their primary plating and secondary expansion.
Indeed a recent article suggests that specific subpopulations of
MSC fail to adhere to tissue culture plastic under standard
conditions [67]. Furthermore, there is growing evidence from
in vitro, preclinical, and clinical studies that the immunosup-
pressive and other trophic functions of culture-expanded
MSCs lose potency over time in culture [68–70]. Addressing
this issue will require new strategies to continuously monitor
the therapeutic potency of MSCs throughout the culture period
and to develop culture conditions which improve or maintain
the key therapeutic effector mechanisms [70]. This process of
optimization may also require tailoring for individual clinical
indications. A third area which may come to bear as regulatory
legislation moves beyond the current focus on manufacturing
sterility and therapeutic toxicology, is the need to better docu-
ment the absorption, distribution, metabolism, and excretion
toxicity (ADMET) profile of clinical-grade MSC products.
Currently there is little or no activity toward understanding the
pharmacokinetic parameters of MSC administration such as
absorption into the blood stream, biodistribution and in
vivo metabolism of MSC-associated biomolecules. In addi-
tion to the regulatory issues, more attention to developing
pharmacokinetic assays for cellular products is also likely
to be of value for accurate calculation of appropriate MSC
dosing regimens and for the testing of strategies to over-
come immune-mediated clearance of systemically adminis-
tered MSCs. Approaches to accurately selecting patients
most likely to benefit from MSC therapies are also gener-
ally lacking and infrequently investigated across the field.
Finally, the need to minimize risk of culture-expanded
MSCs in treated individuals remains an important concern
for the field. For instance, while i.v. infusions of MSCs
appear to be well tolerated in clinical settings, the potential
for acute or chronic adverse effects from entrapment/embo-
lization of cells in the lung or liver should continue to be
carefully evaluated [55,71]. Similarly, despite the paucity of
evidence to date for in vivo transformation of human
MSCs in animal recipients [50], it will only be possible to
accurately define the risk for malignant transformation in
human recipients by performing close surveillance of
treated patients and collating experience from multiple clin-
ical studies into central, shared databases.
Despite the significant gaps in knowledge and focus
described above, there is also reason to be optimistic that
immunomodulatory MSC therapy will establish a foothold for
specific disease entities in the next several years and that this
could subsequently provide the basis for targeted translation
into additional clinical niches. Perhaps the best example of an
immune-mediated disease for which many of the challenges
depicted in Figure 2 have been recognized and are in the
process of being addressed is GvHD. Table 1 summarizes
some of the key developments related to the clinical transla-
tion of MSC therapy for GvHD with a view to highlighting
the important connections that been made across the different
components of the research pipeline. As robust and reproduci-
ble efficacy remains to be unequivocally demonstrated even
for this well-studied disease [70], the continuation of this
translational process for GvHD will be great significance to
the broader field of MSC therapy.
CONCLUSION
To conclude, there can be no doubt that the last decade of
worldwide MSC-related research has generated a highly valu-
able knowledge base that spans fundamental stem cell biol-
ogy, immunology and inflammatory response, disease
pathogenesis, cell manufacture, and the clinical safety of cel-
lular therapeutic products. It has also created the foundations
of an effective clinical intervention for diverse immune/
inflammatory diseases. Whether this progress will be con-
verted into widely used, cost-effective treatment protocols for
large numbers of patients is likely to depend on the degree to
which specific practical challenges that have recently become
apparent are met in coordinated fashion by the various
stakeholders.
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